229 related articles for article (PubMed ID: 30111774)
41. Sialyl-Tn Polysaccharide A1 as an Entirely Carbohydrate Immunogen: Synthesis and Immunological Evaluation.
Shi M; Kleski KA; Trabbic KR; Bourgault JP; Andreana PR
J Am Chem Soc; 2016 Nov; 138(43):14264-14272. PubMed ID: 27726393
[TBL] [Abstract][Full Text] [Related]
42. A combined computational-experimental approach to define the structural origin of antibody recognition of sialyl-Tn, a tumor-associated carbohydrate antigen.
Amon R; Grant OC; Leviatan Ben-Arye S; Makeneni S; Nivedha AK; Marshanski T; Norn C; Yu H; Glushka JN; Fleishman SJ; Chen X; Woods RJ; Padler-Karavani V
Sci Rep; 2018 Jul; 8(1):10786. PubMed ID: 30018351
[TBL] [Abstract][Full Text] [Related]
43. Analysis of the role of type 1 core O-glycans in the binding of anti-MUC1 antibodies by cytofluorometry and synthetic peptide/glycopeptide binding inhibition studies.
Reddish MA; Suresh MR; Koganty RR; Fortier S; Baronic L; Berg A; Longenecker BM
Tumour Biol; 1998; 19 Suppl 1():57-66. PubMed ID: 9422089
[TBL] [Abstract][Full Text] [Related]
44. Expression of human tumor mucin-associated carbohydrate epitopes, including sialylated Tn, and localization of murine monoclonal antibodies CC49 and B72.3 in a syngeneic rat colon carcinoma model.
O'Boyle KP; Goya V; Zuckier LS; Chun S; Bhargava K
J Immunother Emphasis Tumor Immunol; 1994 Nov; 16(4):251-61. PubMed ID: 7533599
[TBL] [Abstract][Full Text] [Related]
45. COSMC knockdown mediated aberrant O-glycosylation promotes oncogenic properties in pancreatic cancer.
Hofmann BT; Schlüter L; Lange P; Mercanoglu B; Ewald F; Fölster A; Picksak AS; Harder S; El Gammal AT; Grupp K; Güngör C; Drenckhan A; Schlüter H; Wagener C; Izbicki JR; Jücker M; Bockhorn M; Wolters-Eisfeld G
Mol Cancer; 2015 May; 14():109. PubMed ID: 26021314
[TBL] [Abstract][Full Text] [Related]
46. Overexpression of tumour-associated carbohydrate antigen sialyl-Tn in advanced bladder tumours.
Ferreira JA; Videira PA; Lima L; Pereira S; Silva M; Carrascal M; Severino PF; Fernandes E; Almeida A; Costa C; Vitorino R; Amaro T; Oliveira MJ; Reis CA; Dall'Olio F; Amado F; Santos LL
Mol Oncol; 2013 Jun; 7(3):719-31. PubMed ID: 23567325
[TBL] [Abstract][Full Text] [Related]
47. Characterization of a new MUC1 monoclonal antibody (VU-2-G7) directed to the glycosylated PDTR sequence of MUC1.
Ryuko K; Schol DJ; Snijdewint FG; von Mensdorff-Pouilly S; Poort-Keesom RJ; Karuntu-Wanamarta YA; Verstraeten RA; Miyazaki K; Kenemans P; Hilgers J
Tumour Biol; 2000; 21(4):197-210. PubMed ID: 10867613
[TBL] [Abstract][Full Text] [Related]
48. Different modes of sialyl-Tn expression during malignant transformation of human colonic mucosa.
Ogata S; Koganty R; Reddish M; Longenecker BM; Chen A; Perez C; Itzkowitz SH
Glycoconj J; 1998 Jan; 15(1):29-35. PubMed ID: 9530954
[TBL] [Abstract][Full Text] [Related]
49. Identification of new cancer biomarkers based on aberrant mucin glycoforms by in situ proximity ligation.
Pinto R; Carvalho AS; Conze T; Magalhães A; Picco G; Burchell JM; Taylor-Papadimitriou J; Reis CA; Almeida R; Mandel U; Clausen H; Söderberg O; David L
J Cell Mol Med; 2012 Jul; 16(7):1474-84. PubMed ID: 21883895
[TBL] [Abstract][Full Text] [Related]
50. Challenges in Antibody Development against Tn and Sialyl-Tn Antigens.
Loureiro LR; Carrascal MA; Barbas A; Ramalho JS; Novo C; Delannoy P; Videira PA
Biomolecules; 2015 Aug; 5(3):1783-809. PubMed ID: 26270678
[TBL] [Abstract][Full Text] [Related]
51. Identification of a novel cancer-specific immunodominant glycopeptide epitope in the MUC1 tandem repeat.
Tarp MA; Sørensen AL; Mandel U; Paulsen H; Burchell J; Taylor-Papadimitriou J; Clausen H
Glycobiology; 2007 Feb; 17(2):197-209. PubMed ID: 17050588
[TBL] [Abstract][Full Text] [Related]
52. Primary breast cancer tumours contain high amounts of IgA1 immunoglobulin: an immunohistochemical analysis of a possible carrier of the tumour-associated Tn antigen.
Welinder C; Baldetorp B; Blixt O; Grabau D; Jansson B
PLoS One; 2013; 8(4):e61749. PubMed ID: 23637900
[TBL] [Abstract][Full Text] [Related]
53. Stable expression of sialyl-Tn antigen in T47-D cells induces a decrease of cell adhesion and an increase of cell migration.
Julien S; Lagadec C; Krzewinski-Recchi MA; Courtand G; Le Bourhis X; Delannoy P
Breast Cancer Res Treat; 2005 Mar; 90(1):77-84. PubMed ID: 15770530
[TBL] [Abstract][Full Text] [Related]
54. Extended half-life target module for sustainable UniCAR T-cell treatment of STn-expressing cancers.
Loureiro LR; Feldmann A; Bergmann R; Koristka S; Berndt N; Máthé D; Hegedüs N; Szigeti K; Videira PA; Bachmann M; Arndt C
J Exp Clin Cancer Res; 2020 May; 39(1):77. PubMed ID: 32370811
[TBL] [Abstract][Full Text] [Related]
55. Expression of MUC1, MUC2 and oligosaccharide epitopes in breast cancer: prognostic significance of a sialylated MUC1 epitope.
Baldus SE; Wienand JR; Werner JP; Landsberg S; Drebber U; Hanisch FG; Dienes HP
Int J Oncol; 2005 Nov; 27(5):1289-97. PubMed ID: 16211224
[TBL] [Abstract][Full Text] [Related]
56. Diverse glycosylation of MUC1 and MUC2: potential significance in tumor immunity.
Irimura T; Denda K; Iida Si; Takeuchi H; Kato K
J Biochem; 1999 Dec; 126(6):975-85. PubMed ID: 10578046
[TBL] [Abstract][Full Text] [Related]
57. Production and characterization of monoclonal antibody against a triple negative breast cancer cell line.
Ghaderi F; Ahmadvand S; Ramezani A; Montazer M; Ghaderi A
Biochem Biophys Res Commun; 2018 Oct; 505(1):181-186. PubMed ID: 30243716
[TBL] [Abstract][Full Text] [Related]
58. A Mucin1 C-terminal Subunit-directed Monoclonal Antibody Targets Overexpressed Mucin1 in Breast Cancer.
Wu G; Kim D; Kim JN; Park S; Maharjan S; Koh H; Moon K; Lee Y; Kwon HJ
Theranostics; 2018; 8(1):78-91. PubMed ID: 29290794
[No Abstract] [Full Text] [Related]
59.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
60.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
